title: Protective murine and human monoclonal antibodies against eczema vaccinatum.
abstract: BACKGROUND
  Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema).
  
  
  METHODS
  Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were developed as a potential therapy for treatment of human eczema vaccinatum.
  
  
  RESULTS
  Using a small animal model of eczema vaccinatum, we demonstrated that both murine and fully human monoclonal antibodies effectively limited eczema vaccinatum disease, foreshortening both the disease kinetics and the severity of the erosive viral skin lesions.
  
  
  CONCLUSIONS
  These neutralizing antibodies would likely be effective at reducing or eliminating clinical disease in people with eczema vaccinatum or other severe side effects of the smallpox vaccine.
authors.affiliation: Division of Cell Biology, La Jolla Institute for Allergy and Immunology (LIAI), La Jolla, CA, USA.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Tomimori
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kawakami
authors.forename: Megan M
authors.initials: MM
authors.lastname: McCausland
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Ando
authors.forename: Lilia
authors.initials: L
authors.lastname: Koriazova
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Kato
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Kawakami
authors.forename: Shane
authors.initials: S
authors.lastname: Crotty
mesh_terms: D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D057134:Antibodies, Neutralizing / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000150:complications / Q000276:immunology; D004195:Disease Models, Animal; D006801:Humans; D007617:Kaposi Varicelliform Eruption / Q000209:etiology / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D051379:Mice; D008815:Mice, Inbred Strains; D020011:Protective Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D012899:Smallpox / Q000276:immunology / Q000517:prevention & control; D012900:Smallpox Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D014611:Vaccination / Q000009:adverse effects*; D014616:Vaccinia virus / Q000276:immunology / Q000472:pathogenicity
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D057134:Antibodies, Neutralizing; D020011:Protective Agents; D012900:Smallpox Vaccine